Login/Register

HLA-G Targeted Exosome Delivering Anticancer Drug (SOB101)

Taiwan
Partnership wanted
Introduction
The "HLA-G targeted exosome for anticancer drug delivery (SOB101)" is a "First-in-Class" pharmaceutical agent. It combines nanobody targeting technology with patented immune checkpoint antibody, as well as the proprietary platform technology of engineered exosome drug delivery system. Utilizing genetic engineering, the nanobody based immune checkpoint antibody (Anti-HLA-G) is expressed on the surface of exosomes outside the bilayer phospholipid membrane. These exosomes serve as targeted vehicles for delivering chemotherapeutic or nucleic acid drugs, enhancing the specificity of exosomal by binding to tumor specific target, HLA-G, and reducing the toxicity of the loaded drugs to normal tissue cells. Additionally, upon binding between HLA-G targeted exosome and HLA-G expressing tumor cells, the immunosuppressive effects caused by HLA-G can be inhibited, augmenting the cytotoxicity of T cells and other immune cells against tumor cells. Preclinical studies have demonstrated the selectvely high tumor affinity of SOB101, enabling specific and effective intracellular delivery of Doxorubicin to cancer cells. It exhibits no cardiotoxicity and minimal impact on normal cells, positioning it as a broad-spectrum anticancer novel drug anticipated for use in the treatment of breast cancer, brain cancer, ovarian cancer, and other solid tumors. Pre-IND/IND is projected to be submitted to the U.S. FDA in 2024.
Features / strengths
The product highlights of SOB101 are as follows:
1. Leading in Asia with Unique HLA-G Targeting: SOA101 is a groundbreaking extracellular vesicle anticancer drug that stands as the sole contender featuring the HLA-G target. This innovative drug simultaneously engages with immune checkpoints on tumor cells and enhances activation of immune cells.
2. Precision through Genetic Engineering of Exosomes: Engineered through genetic modification, SOB101 exudes exceptional specificity as it selectively binds to HLA-G expressing tumor cells. The efficient and safe delivery of therapeutic agents to tumor sites not only enhances the potency but also reduces the required dosage of therapeutic drugs.
3. Versatile Payload Capability: SOB101 accommodates a spectrum of therapeutic agents, including small molecule drugs, nucleic acid-based drugs, and protein-based drugs, broadening its therapeutic potential.
4. Advantages Over Liposomes: In contrast to liposomes, exosomes are naturally generated by cells, offering lower immunogenicity, reduced toxicity, and a diminished likelihood of drug resistance.
5. Broad-Spectrum Anticancer Efficacy: SOB101 represents a revolutionary approach to cancer treatment, with applications spanning various cancer types such as breast cancer, brain cancer, ovarian cancer, and other solid tumors.
Specification in detail
capacity
NA
payload conc.
NA

Information
Introduction
The "HLA-G targeted exosome for anticancer drug delivery (SOB101)" is a "First-in-Class" pharmaceutical agent. It combines nanobody targeting technology with patented immune checkpoint antibody, as well as the proprietary platform technology of engineered exosome drug delivery system. Utilizing genetic engineering, the nanobody based immune checkpoint antibody (Anti-HLA-G) is expressed on the surface of exosomes outside the bilayer phospholipid membrane. These exosomes serve as targeted vehicles for delivering chemotherapeutic or nucleic acid drugs, enhancing the specificity of exosomal by binding to tumor specific target, HLA-G, and reducing the toxicity of the loaded drugs to normal tissue cells. Additionally, upon binding between HLA-G targeted exosome and HLA-G expressing tumor cells, the immunosuppressive effects caused by HLA-G can be inhibited, augmenting the cytotoxicity of T cells and other immune cells against tumor cells. Preclinical studies have demonstrated the selectvely high tumor affinity of SOB101, enabling specific and effective intracellular delivery of Doxorubicin to cancer cells. It exhibits no cardiotoxicity and minimal impact on normal cells, positioning it as a broad-spectrum anticancer novel drug anticipated for use in the treatment of breast cancer, brain cancer, ovarian cancer, and other solid tumors. Pre-IND/IND is projected to be submitted to the U.S. FDA in 2024.
Features / strengths
The product highlights of SOB101 are as follows:
1. Leading in Asia with Unique HLA-G Targeting: SOA101 is a groundbreaking extracellular vesicle anticancer drug that stands as the sole contender featuring the HLA-G target. This innovative drug simultaneously engages with immune checkpoints on tumor cells and enhances activation of immune cells.
2. Precision through Genetic Engineering of Exosomes: Engineered through genetic modification, SOB101 exudes exceptional specificity as it selectively binds to HLA-G expressing tumor cells. The efficient and safe delivery of therapeutic agents to tumor sites not only enhances the potency but also reduces the required dosage of therapeutic drugs.
3. Versatile Payload Capability: SOB101 accommodates a spectrum of therapeutic agents, including small molecule drugs, nucleic acid-based drugs, and protein-based drugs, broadening its therapeutic potential.
4. Advantages Over Liposomes: In contrast to liposomes, exosomes are naturally generated by cells, offering lower immunogenicity, reduced toxicity, and a diminished likelihood of drug resistance.
5. Broad-Spectrum Anticancer Efficacy: SOB101 represents a revolutionary approach to cancer treatment, with applications spanning various cancer types such as breast cancer, brain cancer, ovarian cancer, and other solid tumors.
Specification in detail
capacity
NA
payload conc.
NA

HLA-G Targeted Exosome Delivering Anticancer Drug (SOB101)

Taiwan
Shine-On BioMedical Co., Ltd Other products
Recommended